Gecacitinib as a bridging treatment to allogeneic hematopoietic stem cell transplantation for high-risk myelodysplastic syndrome with Behçet's syndrome: a case report

Scritto il 10/10/2026
da W Wu

Zhonghua Nei Ke Za Zhi. 2026 Oct 1;65(10):1111-1112. doi: 10.3760/cma.j.cn112138-20260703-00410.

ABSTRACT

患者男,40岁,因发热伴全血细胞减少就诊,经骨髓形态学、病理及细胞/分子遗传学检查诊断为高危骨髓增生异常综合征(TP53突变、+8,合并骨髓纤维化),病程中出现腹痛、血便,肠镜及组织病理证实合并肠道白塞综合征,芦可替尼治疗无效。改用吉卡昔替尼(100 mg、2次/d)后骨髓原始细胞比例下降、肠道溃疡愈合,持续用药下成功桥接同胞全相合异基因造血干细胞移植,造血重建顺利,随访期间未发生移植物抗宿主病。.

PMID:42855759 | DOI:10.3760/cma.j.cn112138-20260703-00410